Cohance Lifesciences Ltd. Share Price

Cohance Lifesciences: Can ADCs Become the Next Growth Driver

# Cohance Lifesciences: Can ADCs Become the Next Growth Driver? Cohance Lifesciences, formerly Suven Pharmaceuticals, is building an integrated pharmaceutical services platform spanning CDMO, APIs, formulations and specialty capabilities. **What is changing?** The company is increasingly focusing on high-value CDMO opportunities, including antibody-drug conjugates (ADCs). Its investment in NJ Bio provides access to specialised ADC capabilities, while Cohance has continued developing its broader bioconjugation platform. The company announced further progress on its ADC strategy in September 2026. **Why does this matter?** ADCs combine targeted biological therapies with potent drug payloads and are attracting increasing interest from global pharmaceutical companies. For a CDMO, participation in this segment could potentially provide higher-value contracts and deeper relationships with innovators. **What investors should track** - New CDMO contracts and customer additions - ADC and bioconjugation capacity utilisation - Revenue contribution from high-value projects - Regulatory clearances and compliance - Cash flow and returns on expansion **Key takeaway:** Cohance’s long-term opportunity lies in moving towards specialised, higher-value pharmaceutical services. Successful execution in ADCs and complex CDMO programs could strengthen the business mix, but commercialisation, regulatory execution and return on invested capital remain key variables. **Disclosure:** I am a SEBI Registered Research Analyst. This content is for educational purposes and is not a recommendation to buy or sell any security. **Suggested tags:** Fundamental Views + Equity Research + Pharmaceuticals

See More

Suven Pharma: Building a nucleic-acid CDMO platform

# Suven Pharma: Building a nucleic-acid CDMO platform Suven Pharmaceuticals, now Cohance Lifesciences Limited, is repositioning its business toward higher-value CDMO opportunities. The key focus is building an integrated nucleic-acid platform while expanding its capabilities for innovator customers. The company has identified nucleic acids as one of its strategic growth areas and is working toward an integrated offering covering development and manufacturing. This is important because CDMO customers increasingly prefer suppliers that can handle multiple stages of a drug-development programme rather than supplying only a single intermediate or API. Suven's earlier strategy was already moving up the value chain, from intermediates toward APIs and more complex molecules. Its pipeline had also expanded significantly, with increasing RFQs and Phase III opportunities. The latest strategy takes that approach further. However, the transition comes with a near-term cost. Q1 FY27 was weak, with revenue affected by shipment and order phasing, an unfavourable product mix and negative operating leverage. Management expects sequential improvement from Q2 and a return to growth during H2 FY27. **My view:** The important Suven story is not the next quarter alone. It is whether investments in complex chemistry and nucleic acids can create a larger, higher-value CDMO platform over the next few years. I would watch new customer additions, Phase III-to-commercial conversions, nucleic-acid order wins and margin recovery. **What I'm watching:** CDMO order inflows, pipeline conversion, nucleic-acid capacity, H2 FY27 growth and EBITDA margins. **Stance:** The strategic transition is promising to track, but execution and conversion of the pipeline into commercial revenue remain the key tests. **Disclosure:** I am a SEBI Registered Research Analyst. Please refer to the applicable disclosures before taking any investment decision.

See More

Cohance Extends Losses After USFDA Form 483 Observations

Cohance Lifesciences fell for a second session after its Telangana facility received four USFDA observations following a recent inspection. Cohance Lifesciences Ltd. (NSE:

) extended its decline for the second consecutive trading session on September 7, 2026, with the stock falling 1.54% to close at ₹449.55. The stock remains under pressure as investors assess the latest regulatory development. The United States Food and Drug Administration (USFDA) inspected the company's formulation (FDF) facility in Shamshabad, Telangana, between August 27 and September 4, 2026. The inspection concluded with the issuance of a Form FDA 483 containing four observations. Stock Snapshot Closing Price: ₹449.55 Change: -1.54% (-₹7.05) Market Capitalisation: ₹17,733 crore 52-Week Range: ₹266.70 – ₹1,038.90 Despite the recent weakness, the stock has recovered more than 68% from its 52-week low of ₹266.70. However, it remains approximately 67% below its all-time high of ₹1,360, recorded in December 2024. The regulatory observations and the company's subsequent corrective actions are likely to remain key areas of focus for investors. Market participants will closely monitor management commentary and future regulatory updates to assess the potential impact on operations and business performance. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

See More

Cohance Lifesciences Limited Latest Updates

US FDA Inspection Completed with Four Observations at Shamshabad Facility On September 5, 2026, the company informed stock exchanges under Regulation 30 disclosures that the US FDA concluded an inspection at its formulation (Finished Dosage Form - FDF) manufacturing facility located in Shamshabad, Telangana. The inspection, carried out up to September 4, 2026, closed with the issuance of Form FDA 483 containing four inspectional observations. The company stated that none of the observations pertain to data integrity and confirmed that it is actively preparing a comprehensive response with corrective and preventive action (CAPA) plans within the prescribed timeline. Q1 FY27 Financial Results & Bottom-Line Contraction In August 2026, Cohance Lifesciences reported its consolidated financial results for the first quarter ended June 30, 2026 (Q1 FY27). Consolidated total income stood at ₹434.51 crore, contracting from ₹563.48 crore in Q1 FY26, impacted by timing of customer batches and inventory rationalization across CDMO innovator accounts. The company posted a consolidated net loss (PAT) of ₹24.12 crore (compared to a profit after tax of ₹48.88 crore in the corresponding prior-year period), leading to an operational margin compression during the quarter. Key Leadership Changes & Executive Transition Under senior management governance disclosures, Chief Financial Officer (CFO) Himanshu Agarwal tendered his resignation to pursue external opportunities, with his formal relief from executive responsibilities effective September 13, 2026. The Board initiated the succession and appointment process to transition the finance leadership portfolio smoothly ahead of upcoming capital planning milestones.

See More

Cohance Lifesciences Expands ADC Push Amid Stock Weakness

Cohance Lifesciences plans $18 million in ADC-focused investments, while the stock remains nearly 66% below its December 2024 peak. Cohance Lifesciences Ltd. (NSE:

) is strengthening its presence in the rapidly growing antibody-drug conjugate (ADC) segment through two proposed strategic investments worth $18 million. The company plans to invest an additional $13 million in NJ Bio and deploy $5 million to acquire a controlling stake in Aruka Bio. Both transactions are expected to be funded through internal accruals and are aimed at enhancing Cohance's capabilities across ADC research, development and manufacturing. Despite the strategic expansion (proposed), investor sentiment remained cautious. Cohance Lifesciences shares closed at ₹456.60 on September 4, 2026, down 0.92% for the session. The stock has largely traded in a broad range over the past four months following a sharp correction from its historic highs. From its all-time high of ₹1,360, recorded in December 2024, the stock is trading down by approximately 66%. It also touched a 52-week low of ₹267.85 in March 2026 (the stock has declined over 80% from its all time high). The proposed investments underscore the company's long-term focus on expanding its presence in high-growth pharmaceutical segments. However, investors are likely to remain focused on execution, revenue contribution from these investments and the company's ability to translate strategic initiatives into sustainable growth and profitability. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

See More

Cohance Faces USFDA Observations at Telangana Plant

Cohance Lifesciences is in focus after the USFDA completed an inspection of its Shamshabad formulation facility in Telangana. The inspection, conducted from August 27 to September 4, 2026, concluded with four observations issued through Form FDA 483. The company said it has initiated corrective and preventive actions (CAPA) and will submit its response to the regulator within the stipulated timeline. The observations could remain a near-term overhang until the company addresses the regulatory concerns. Separately, Cohance has announced a strategic investment of $18 million in NJ Bio and Aruka Bio to strengthen its antibody-drug conjugate (ADC) capabilities. The investment is aimed at expanding its global CRDMO platform and integrated ADC offerings. Investors will now track the company’s response to the USFDA observations along with the progress of its ADC expansion strategy. Successful remediation and execution of new investments could support long-term growth, while regulatory developments remain a key near-term factor for the stock.

See More